51
3
259
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP2270 |
MHC class II antigen (45-57) [Homo sapiens]
|
Others | Others |
MHC class II antigen (45-57) [Homo sapiens] is a peptide with the sequence H2N-Asp-Leu-Asp-Lys-Lys-Glu-Thr-Val-Trp-His-Leu-Glu- Glu-OH, MW= 1868.07. MHC (major histocompatibility complex) class II molecules are found only on antigen-presenting cells and l | |||
T8005 |
Cardiogenol C hydrochloride
2-[[2-[(4-甲氧基苯基)氨基]-4-嘧啶基]氨基]乙醇盐酸盐,Cardiogenol C HCl,Cardiogenol C |
Wnt/beta-catenin | Cytoskeletal Signaling; Stem Cells |
Cardiogenol C hydrochloride (Cardiogenol C) 是一种细胞渗透性嘧啶诱导剂,能够促使 ESCs 分化为心肌细胞。在有限的可塑性范围内,它可以对已经沿袭的祖细胞类型产生心肌生成效应,是一种心肌生成试剂,在动物模型中可以用作细胞移植研究中提高心脏修复的工具。 | |||
T2161 |
Cardiogenol C
|
Wnt/beta-catenin | Cytoskeletal Signaling; Stem Cells |
Cardiogenol C 是一种细胞渗透性嘧啶诱导剂,能够诱导 ESCs 分化为心肌细胞(EC50:100 nM)。在有限的可塑性范围内,它可以对已经沿袭的祖细胞类型产生心肌病,是一种心肌发生剂。 | |||
T40898 |
DMHCA
|
||
DMHCA, a potent, selective LXR agonist, specifically activates the LXR pathway's cholesterol efflux arm, avoiding triglyceride synthesis stimulation. This compound exhibits anti-inflammatory properties and is utilized in researching cholesterol homeostasis and diabetes. | |||
TP2502 |
KYGVSVQDI Acetate
|
Others | Others |
KYGVSVQDI Acetate 是编码来自Listeria monocytogenes 的 MHC I 类限制性肽 p60(217-225) 的 DNA 序列。 | |||
TP1591L |
OVA G4 peptide acetate(148274-82-2 free base)
SIIGFEKL acetate |
Others | Others |
OVA G4 peptide acetate(148274-82-2 free base) (SIIGFEKL acetate) 是激动剂卵清蛋白 (OVA) 肽 (257-264) SIINFEKL 的变体。 OVA 肽是卵清蛋白的 I 类 (Kb) 限制性肽表位,由 I 类 MHC(主要组织相容性复合物)分子 H-2Kb(小鼠 MHC I 类基因)呈递。 | |||
TP1327L |
OVA Peptide 257-264 2TFA (138831-86-4 free base)
OVA Peptide 257-264 2TFA 1262751-08-5(TFA-2TFA) |
Others | Others |
OVA Peptide 257-264 2TFA (138831-86-4 free base) 是 OVA 的 I 类 (Kb) 限制性肽表位,OVA 是卵清蛋白的八聚体肽,由 I 类 MHC 分子 H-2Kb 呈递。 | |||
TP1777L |
p2Ca acetate(142606-55-1 free base)
|
Others | Others |
p2Ca acetate(142606-55-1 free base) 是一种天然加工的肽,来源于普遍存在的酶 α-酮戊二酸脱氢酶,并被 CTL 克隆 (2C) 识别为与 I 类 MHC 蛋白 Ld 结合。 | |||
T73133 |
FGF22-IN-1
|
Others | Others |
FGF22-IN-1 是一种潜在的 CD4 N-末端免疫球蛋白可变区样结构域(CD4 D1)抑制剂。FGF22-IN-1 可抑制CD4 与主要组织相容性复合体 (MHC) II 类蛋白之间的相互作用,抑制免疫应答。 | |||
T9901A-001 |
Relatlimab
BMS-986016 |
Others | Others |
Relatlimab(BMS-986016) 是一种靶向人抗 LAG-3 的单克隆抗体,由携带重组 LAG-3 蛋白的人免疫球蛋白的转基因小鼠免疫生成。Relatlimb 有阻断作用,可阻断 LAG-3/MHC II 的相互作用(IC50 : 0.67 nM),阻断了 LAG-3/FGL1 的相互作用( IC50:0.019 nM)。Relatlimab 常与 Nivoluma 一起用来治疗晚期黑色素瘤。 | |||
TP1543L |
G280-9 acetate(156761-76-1 free base)
|
Others | Others |
G280-9 acetate(156761-76-1 free base) 是一种常见的黑色素瘤 gp100 表位,受 MHC 相关 HLA-A2 限制。 G280-9 序列是独特的,因为它可以在非常低的浓度下被细胞毒性 T 淋巴细胞识别,但是它显示出低的总免疫原性,这可能是由于该肽对 HLA-A2 的亲和力相对较低。 | |||
T12079 |
ML604440
|
Proteasome | Proteases/Proteasome; Ubiquitination |
ML604440 是一种特异性的、有效的、细胞可渗透的蛋白酶体 β1i (LMP2) 亚基抑制剂,能够破坏 MHC I 类细胞表面表达,IL-6 分泌以及 naïve T helper 向 17 T helper 细胞的分化。它可以改善实验性结肠炎和 EAE 疾病。 | |||
TP2315 |
glatiramer Acetate
|
Others | Others |
Glatiramer acetate 是髓鞘碱性蛋白的合成类似物和免疫调节剂,可用于多发性硬化症的研究。它能够诱导 T 辅助细胞 2 的特异性抑制细胞迁移到大脑并导致原位旁观者抑制。它能够于 MHC 分子强而杂乱的结合,因此与各种髓鞘抗原竞争,使其呈现给 T 细胞。 | |||
TP2360 |
A2-Binding peptide
|
||
A2-Binding peptide has involved in the assembly of MHC Class I molecules. | |||
TP1591 |
OVA G4 peptide
|
||
G4 peptide (SIIGFEKL) is a variant of the agonist ovalbumin (OVA) peptide (257-264), SIINFEKL. OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC). | |||
TP1327 |
OVA Peptide(257-264) TFA
OVA Peptide (257-264) TFA |
||
OVA Peptide (257-264) TFA, an octameric peptide epitope from ovalbumin, is presented by the class I MHC molecule, H-2Kb, showcasing a class I (Kb)-restricted profile. | |||
T83861 |
Bactobolamine
|
||
Bactobolamine是一种免疫抑制剂。在200 µg/ml的浓度下,该化合物能够抑制CTLL细胞的IL-2产生。在体内实验中,Bactobolamine(200 mg/kg)能够延长MHC兼容及MHC不兼容的大鼠心脏移植物存活时间。此外,它还能在大鼠肝脏移植模型和犬类肾脏移植模型中延长存活时间。 | |||
TP1126 |
InsB 9-23
Insulin B chain (9-23) |
||
InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. | |||
T36116 |
Concanamycin B
|
||
Concanamycin B is a macrolide antibiotic that selectively inhibits vacuolar type H+-ATPases, also known as V-ATPases (IC50 = 5 nM). In this way, it blocks the acidification of vacuolar organelles as well as early to late endosomal transport. Concanamycin B interferes with bone resorption and maturation of CD8 T lymphocytes. It also prevents processing of major histocompatibility complex (MHC) class II precursors in human B cells, inhibiting the expression of MHC class II molecules on the cell su... | |||
T78247 |
Ieramilimab
IMP701,LAG525 |
||
Ieramilimab(LAG525;IMP701)是一款针对LAG-3的人源化IgG4单克隆抗体,它通过结合到LAG-3来阻断其与MHC-II 分子的相互作用。 | |||
T76529 |
HBV Seq2 aa:28-39
|
||
HBVSeq2 aa:28-39 是一种 HBsAg 肽,可与主要组织相容性复合体 (MHC) I 类分子结合。 | |||
TP1652 |
OVA G4 peptide TFA (148274-82-2 free base)
OVA G4 peptide TFA |
||
OVA G4 peptide TFA is an TFA salt form of OVA G4 peptide. G4 peptide (SIIGFEKL) is a variant of the agonist ovalbumin (OVA) peptide (257-264), SIINFEKL. OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC). | |||
T81590 |
OVA peptide
|
||
OVA peptide,主要源于鸡蛋清,作为I类MHC(主要组织相容性复合体)分子H-2Kb(小鼠MHC的I类基因)所呈递的特定卵白蛋白Kb限制性表位。在过敏性研究领域,OVA peptide具有广泛应用。 | |||
TP1589 |
EGFRvIII peptide (PEPvIII)
EGFRvIII peptide PEPvIII |
||
PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes. | |||
T38794 |
LLO (91-99)
LLO (91-99),Listeriolysin O (91-99) |
||
LLO (91-99), also known as Listeriolysin O (91-99), is a class I MHC-restricted T-cell epitope derived from listeriolysin (LLO), an exotoxin. It plays a vital role as an antigen in the induction of T-cell mediated immunity in vivo. | |||
T82743 |
CFP10 (71–85)
|
||
CFP10 (71–85) 是具生物活性的肽类,能激活表达不同MHC II类与I类分子的人类CD4+和CD8+ T细胞,诱导IFN-γ产生及CTL活性。(CFP10 71–85). | |||
T7619 |
OVA Peptide(257-264)
OVA Peptide 257-264,OVA Peptide 257-264 (2TFA) |
Others | Others |
OVA Peptide(257-264) 是 OVA 的 I 类 (Kb)-限制性肽表位,其中OVA 是一种来自卵清蛋白的八聚体肽,由 I 类 MHC 分子 H-2Kb 所呈递。 | |||
T39005 |
OVA (55-62)
|
||
OVA 55-62 is a truncated peptide derived from the ovalbumin (OVA) antigen, specifically designed to bind to the H2-Kb mouse major histocompatibility complex (MHC) class I molecule. | |||
T80907 |
TYVPANASL
|
||
TYVPANASL为由HER2/neu的9个氨基酸组成的MHC I结合CD8 T细胞表位,可用于制备J-LEAPS疫苗。 | |||
T40115 |
GAD65 (206-220)
GAD65 (206-220) |
||
GAD65 (206-220) is a synthetic peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 180-188. It is known that GAD65 interacts with I-Ag7 MHC class II molecules and is a significant pancreatic antigen that self-reactive T cells target in type I diabetes mellitus. | |||
T40590 |
NY-ESO-1 (87-111)
|
||
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide that interacts with various HLA-DR and HLA-DP4 molecules, inducing activation of CD4+ T cells with Th1-type and Th-2/Th0-type responses, when presented in conjunction with HLA-DR and HLA-DP4 molecules. | |||
TP1777 |
p2Ca
|
||
p2Ca, a naturally processed peptide that derives from a ubiquitous enzyme, alpha-ketoglutarate dehydrogenase, and is recognized in association with the class I MHC protein, Ld, by a CTL clone (2C). | |||
T75982 |
LCMV gp33-41 TFA
|
||
LCMV gp33-41 (TFA)是一种带有羧基延伸的11-aa长肽,作为淋巴细胞脉络丛脑膜炎病毒序列,在MHC I类H-2Db分子的限制下,能够被呈递给细胞毒性T淋巴细胞。 | |||
T81790 |
Miptenalimab
BI-754111 |
||
Miptenalimab (BI-754111)为一种高亲和力抗人LAG-3抗体,其对hLAG-3的结合常数(KD)为88.6 nM。该抗体能有效阻断LAG-3与其主要配体MHC-II之间的相互作用。 | |||
T38794L |
LLO (91-99) acetate
LLO (91-99) acetate(137856-41-8 free base) |
Others | Others |
LLO (91-99) acetate 是一种外毒素,是李斯特菌溶血素的 I 类 MHC 限制性 T 细胞表位。 LLO (91-99) 醋酸盐对于诱导体内 T 细胞介导的免疫至关重要。 | |||
T80906 |
TYVPANASL TFA
|
||
TYVPANASL TFA,一种由HER2/neu的9个氨基酸组成,可结合MHC I并与CD8 T细胞表位相关的化合物。该化合物可用于制备J-LEAPS疫苗。 | |||
T80857 |
VLHDDLLEA
|
||
VLHDDLLEA是从MHC复合体HLA-A*0201分子中分离得到的多肽,具有被HLA-A*0201-限制性细胞毒T细胞(CTLs)识别的特性。该多肽可应用于移植物抗宿主病(GvHD)的研究。 | |||
T82414 |
Favezelimab
MK-4280 |
||
Favezelimab(MK-4280)为人源化抗LAG-3单克隆抗体,能够抑制LAG-3与其配体MHC II类结合。该抗体联合PD-L1抑制剂Pembrolizumab在结直肠癌(CRC)治疗研究中展现出应用前景。 | |||
T82471 |
Encelimab
|
||
Encelimab是一种抗LAG3抗体,能够阻断 LAG-3 与 MHC II 的交互作用并增强T细胞活性。在单独应用或与抗PD-1抗体结合时,Encelimab能有效减小A20细胞异种移植瘤小鼠模型中的淋巴瘤肿瘤体积。 | |||
TP1502 |
MAGE-A3 (195-203)
MAGE-A3 195-203 |
||
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in | |||
T78332 |
Eftilagimod alfa
IMP321,LAG-3Ig |
||
Eftilagimod alfa为重组LAG-3Ig融合蛋白,具有MHC II 类分子结合能力。该药物通过介导抗原提呈细胞(APC)的激活进而激活CD8 T细胞,可用于研究转移性黑色素瘤及转移性乳腺癌。 | |||
T39311 |
Tyrosinase-related Protein 2 (TRP-2) (181-188)
|
||
Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide derived from the tyrosinase-related protein 2 (TRP-2), specifically corresponding to residues 180-188. It is the primary epitope within TRP-2 that is recognized by anti-B16 CTLs. Moreover, It is a peptide that conforms to the binding motif of the MHC class I H2-Kb. | |||
TP1543 |
G280-9
|
||
The G280-9 peptide, a common melanoma gp100 epitope restricted by MHC-associated HLA-A2. The G280-9 sequence is unique because it could be recognized by cytotoxic T lymphocytes at very low concentrations, however it shows low total immunogenicity that may | |||
TP1629 |
LCMV gp33-41 (TFA) (151705-84-9 free base)
LCMV gp33-41 (TFA) |
||
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1]. | |||
TP1758 |
LCMV gp33-41
|
||
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.This is the H-2Db restricted epitope derived from the lymphocytic | |||
T76985 | Tebotelimab | ||
Tebotelimab (MGD-013) 是一种人源的 IgG4κ 双特异性 PD-1/LAG-3双亲和再靶向 (DART) 抗体。Tebotelimab 结合 NS0 细胞表面表达的 PD-1和 LAG-3,EC50分别为 1.65 nM 和 0.41 nM。Tebotelimab 阻断 PD-1/PD-L1、PD-1/PD-L2 和 LAG-3/HLA (MHC-II) 相互作用和 PD-1信号。Tebotelimab 可恢复耗尽的 T 细胞功能并增强抗肿瘤免疫力。 | |||
T81423 |
Polzastobart
JTX 8064 |
||
Polzastobart (JTX-8064) 为一种人源化IgG4单克隆抗体,特异性与LILRB2结合,阻断其与配体及MHC I分子(经典与非经典)的相互作用。此抗体通过抑制LILRB2与HLA-A/B和/或HLA-G(癌细胞免疫耐受的标志)的结合,可增强巨噬细胞产生促炎细胞因子。Polzastobart 作为巨噬细胞免疫检查点抑制剂发挥作用。 | |||
TP1855 |
Moth Cytochrome C (MCC) (88-103)
Moth Cytochrome C (MCC) 88-103 |
||
Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes.This peptide is derived from the carboxyl terminus of moth cytochrome c. Thymic positive and negative select | |||
T83852 |
EGFRvIII Peptide TFA
PEGFRvIII (9-mer),Epidermal Growth Factor Receptor Variant III Peptide |
||
EGFRvIII peptide是一种合成肽,对应于特异性肿瘤、具有持续激活性的EGFR变体EGFRvIII的融合接头,该变体缺少野生型EGFR的第6至273个氨基酸。在25 µg/ml的浓度下,它能与MHC I类亚型HLA-A*0201阳性的T2细胞结合。在用于分离的人外周血单个核细胞(PBMCs)衍生的树突状细胞中,EGFRvIII peptide可诱导抗原呈递,进而刺激CD8+细胞毒性T淋巴细胞的激活和IFN-γ产生。与toll样受体5(TLR5)激动剂鞭毛蛋白B共同免疫EGFRvIII peptide(15 µg/动物),在正交GL261胶质母细胞瘤小鼠异种移植模型中,增加了CD8+ T细胞数量,减少了调节性T细胞(Tregs)数量,减少了肿瘤体积,并提高了生存率。 | |||
T36984 |
Cyclic di-IMP (sodium salt)
|
||
Cyclic di-IMP (sodium salt) (c-di-IMP) is a synthetic second messenger structurally related to the bacterial second messengers cyclic di-GMP and cyclic di-AMP . C-di-IMP has adjuvant properties when co-administered with antigens in vitro and by mucosal routes in vivo. C-di-IMP enriches the population of MHC class I and II, CD80, CD86, CD40, and CD54 positive dendritic cells derived from murine bone marrow. It also stimulates macrophages at 500 ng/ml. Mice immunized with β-galactosidase (β-gal) p... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0948L |
Corticosterone
皮质酮,17-Deoxycortisol,11β,21-Dihydroxyprogesterone,Kendall's compound B,肾上腺酮,Corticosterone (From plants) |
Glucocorticoid Receptor; Endogenous Metabolite | Endocrinology/Hormones; Metabolism |
Corticosterone (Kendall's compound B) 是一种肾上腺皮质类固醇,有盐皮质激素和糖皮质激素的活性,具有口服活性。Corticosterone 参与体内能量、免疫反应和应激反应的调节。 | |||
T5771 |
Hypocrellin A
|
Antibacterial; PKC; Parasite | Chromatin/Epigenetic; Cytoskeletal Signaling; Microbiology/Virology |
Hypocrellin A 是一种天然的PKC 抑制剂,具有光诱导的抗肿瘤、抗真菌和抗病毒活性,还对 MHC 限制性抗原呈递发挥免疫调节作用。 | |||
TN6925 |
Pristane
姥鲛烷,2,6,10,14-tetramethylpentadecane |
Others | Others |
Pristane (2,6,10,14-tetramethylpentadecane) 是一种天然存在的烃油,是矿物油中最活跃的成分,较少存在于许多植物、各种海洋生物中。它是一种非抗原性佐剂,可诱导大鼠中 MHC II 类限制性关节炎 T 细胞。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-05476 |
MICA Protein, Cynomolgus, Recombinant (His)
MHC class I polypeptide-related sequence A |
Cynomolgus | HEK293 Cells |
MICA Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 34.3 kDa and the accession number is A9UJR3. | |||
TMPY-01066 |
MICB Protein, Human, Recombinant (His)
MHC class I polypeptide-related sequence B,PERB11.2 |
Human | HEK293 Cells |
MICB Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 33 kDa and the accession number is A0A7D9H7X8. | |||
TMPK-01545 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
sHLA-E,MHC,MHC class I antigen E,HLAE,... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01544 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein, Human, MHC (His & Avi)
MHC class I antigen E,HLAE,sHLA-E,QA1,MHC ... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01494 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A*0101,HLA class I,MHC,MHC HLA-A... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01514 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein, Human, MHC (His & Avi)
sHLA-E,MHC class I antigen E,MHC HLA-E alp... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01496 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Monomer Protein, Human, MHC (His & Avi)
HLA-A,CT83,HLA-A*0101,HLA class I,MHC class I,M... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01541 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein, Human, MHC (His & Avi), Biotinylated
QA1,MHC HLA-E alpha-2.1,MHC,HLAE,MHC |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01504 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)
MHC,HPV16,E7 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01506 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)
HPV16,E7,MHC |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01516 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein, Human, MHC (His & Avi)
IAP4,survivin variant 3 alpha,BIRC5,Survivin,EPR-1,API4,... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01505 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated
E7,MHC,HPV16 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01418 |
Peptide Ready HLA-G&B2M Monomer Protein, Human, MHC (His & Avi)
MHC,HLA-G,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01480 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
IAP4,Survivin,API4,BIRC5,MHC,MHC I,EPR-1,s... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01501 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
MHC,Hepatitis B virus,HBV |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01492 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Hepatitis B virus,HBV,MHC |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01452 |
HLA-E*01:03&B2M&Peptide (VMAPKTLVL) Monomer Negative Control Protein, Human, MHC (His & Avi)
HLAE,MHC class I antigen E,MHC,QA1,sHLA-E |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01517 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi)
survivin variant 3 alpha,MHC I,BIRC5,EPR-1,IAP4,Sur... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01491 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HBV,Hepatitis B virus |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01411 |
Peptide Ready HLA-G&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,HLA-G,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01413 |
H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi)
H-2K,OVA,MHC,H2-K1 |
Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se... | |||
TMPK-01414 |
Qa-1b&B2M&Qdm (AMAPRTLLL) Monomer Protein, Mouse, MHC (His & Avi)
Qa-1b,Qdm,MHC,H2-T23 |
Mouse | HEK293 Cells |
Qa-1b binds a peptide (AMAPRTLLL), referred to as Qdm (for Qa-1 determinant modifier), derived from the signal sequence of murine class Ia molecules. This peptide binds with high affinity and accounts for almost all of the peptides associated with this molecule. Human histocompatibility leukocyte antigen (HLA)-E, a homologue of Qa-1b, binds similar peptides derived from human class Ia molecules and interacts with CD94/NKG2 receptors on natural killer cells. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01412 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi)
SARS-CoV-2 epitope,MHC |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01424 |
Peptide Ready HLA-E*01:03&B2M Monomer Protein, Human, MHC (His & Avi)
MHC,HLA-E*01:03,Peptide Ready |
Human | HEK293 Cells |
HLA-E*01:03&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-E*01:03. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01416 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,SARS-CoV-2 epitope |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01423 |
Peptide Ready HLA-E*01:03&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,Peptide Ready,HLA-E*01:03 |
Human | HEK293 Cells |
HLA-E*01:03&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-E*01:03. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01540 |
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Tetramer Protein, Human, MHC (His & Avi)
HLA0201,P100,MHC I,gp100,Glycoprotein 100,ME20-M |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. | |||
TMPK-01551 |
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer Protein, Human, MHC (His & Avi)
MHC I,ME20-M,Glycoprotein 100,gp100,P100,HLA0201 |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. | |||
TMPK-01554 |
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein, Human, MHC (His & Avi)
WT1,WT33,WIT-2,NPHS4GUD,AWT1,GUD,WAGR,MHC,RMF |
Human | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01484 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,FETA,AFP,AFPD,Alpha-1-fetoprotein,MHC,Alpha-f... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01520 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPAFP,FETA,AFPD,MHC,Alpha-f... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01519 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,AFPD,Alpha-1-fetoprotein,HP... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01553 |
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA0201,ME20-M,gp100,MHC I,Glycoprotein 100,P100 |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I and YLEPGPVTA peptide of the gp100. | |||
TMPK-01549 |
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein, Human, MHC (His & Avi)
RMF,WAGR,MHC,GUD,NPHS4GUD,WT1,WT33,WIT-2,AWT1 |
Human | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01515 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,Alpha-fetoprotein,MHC,FETA,Alpha-feto,Alpha-1... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-fetoprotein,AFPD,AFP,Alpha-feto,MHC |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01548 |
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,WIT-2,AWT1,GUD,WAGR,WT1,NPHS4GUD,WT33,RMF |
Human | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01550 |
HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein, Human, MHC (His & Avi)
MAGE4B,MAGE-A4,member 4,CT1.4,HLA0201,MAGE4A,MAGE-X2,MHC... |
Human | HEK293 Cells |
Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene.The MAGE- A4 antigen is among the most commonly expressed cancer testis antigens. The Human HLA-A*0201 MAGE-A4 (GVYDGREHTV) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and GVYDGREHTV peptide of the MAGE-A4. | |||
TMPK-01524 |
HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer Protein, Human, MHC (His & Avi)
CT1.4,MAGE-A4,MAGE4A,HLA0201,MAGE4B,MHC I,MAGE-X2,m... |
Human | HEK293 Cells |
Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene.The MAGE- A4 antigen is among the most commonly expressed cancer testis antigens. The Human HLA-A*0201 MAGE-A4 (GVYDGREHTV) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and GVYDGREHTV peptide of the MAGE-A4. | |||
TMPK-01483 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
AFPD,AFP,Alpha-fetoprotein,HPAFP,MHC,FETA,Alpha-1-f... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01521 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi)
MHC,Alpha-feto,AFPD,Alpha-1-fetoprotein,Alpha-fetop... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
------------------------ 更多 ------------------------ |